Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2006)
Evaluation of the psychometric properties of a gout-specific patient reported outcomes (PRO) instrument [abstract
K. Saag, Hyon Choi (2006)
Epidemiology, risk factors, and lifestyle modifications for goutArthritis Research & Therapy, 8
Karissa Kim, H. Schumacher, E. Hunsche, A. Wertheimer, S. Kong (2003)
A literature review of the epidemiology and treatment of acute gout.Clinical therapeutics, 25 6
Gregory Borstad, L. Bryant, M. Abel, D. Scroggie, M. Harris, J. Alloway (2004)
Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.The Journal of rheumatology, 31 12
J. Bosch, G. Bonsel, K. Moons, C. Kalkman (2006)
Effect of Postoperative Experiences on Willingness to Pay to Avoid Postoperative Pain, Nausea, and VomitingAnesthesiology, 104
C. Sarawate, P. Patel, Wenya Yang, K. Brewer, A. Bakst (2006)
Serum Urate Levels and Gout Flares: Analysis From Managed Care DataJCR: Journal of Clinical Rheumatology, 12
Harry Campbell, Richard Brown (2015)
Cost-Benefit Analysis
M. Becker, H. Schumacher, R. Wortmann, P. Macdonald, Denise Eustace, W. Palo, Janet Streit, N. Joseph‐Ridge (2005)
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.The New England journal of medicine, 353 23
Magnus Johannesson (1992)
Economic evaluation of lipid lowering--a feasibility test of the contingent valuation approach.Health policy, 20 3
S. Wallace, H. Robinson, A. Masi, J. Decker, D. Mccarty, Ts'Ai‐Fan Yu (1977)
Preliminary criteria for the classification of the acute arthritis of primary gout.Arthritis and rheumatism, 20 3
B. O'brien, A. Gafni (1996)
When Do the "Dollars" Make Sense?Medical Decision Making, 16
N. Kleinman, R. Brook, P. Patel, A. Melkonian, Truman Brizee, J. Smeeding, N. Joseph‐Ridge (2007)
The impact of gout on work absence and productivity.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 10 4
E. Frew, J. Wolstenholme, D. Whynes (2004)
Comparing willingness-to-pay: bidding game format versus open-ended and payment scale formats.Health policy, 68 3
U. Slothuus, R. Brooks (2000)
Willingness to pay in arthritis: a Danish contribution.Rheumatology, 39 7
R. Schiffner, J. Schiffner-Rohe, M. Gerstenhauer, Ferdinand Hofstädter, M. Landthaler, Wilhelm Stolz (2003)
Willingness to pay and time trade‐off: sensitive to changes of quality of life in psoriasis patients?British Journal of Dermatology, 148
S. Ramsey, S. Sullivan, B. Psaty, D. Patrick (1997)
Willingness to pay for antihypertensive care: evidence from a staff-model HMO.Social science & medicine, 44 12
R. Brook, N. Kleinman, P. Patel, A. Melkonian, Truman Brizee, J. Smeeding, N. Joseph‐Ridge (2006)
The economic burden of gout on an employed populationCurrent Medical Research and Opinion, 22
E. Frew, D. Whynes, J. Wolstenholme (2003)
Eliciting Willingness to Pay: Comparing Closed-Ended with Open-Ended and Payment Scale FormatsMedical Decision Making, 23
H. Yasunaga, Hiroo Ide, T. Imamura, K. Ohe (2006)
Willingness to pay for health care services in common cold, retinal detachment, and myocardiac infarction: an internet survey in JapanBMC Health Services Research, 6
(2000)
How to Score Version Two of the SF-36
M. Ryan, D. Scott, C. Donaldson (2004)
Valuing health care using willingness to pay: a comparison of the payment card and dichotomous choice methods.Journal of health economics, 23 2
A. Detsky, A. Laupacis (2007)
Relevance of cost-effectiveness analysis to clinicians and policy makers.JAMA, 298 2
M. Cross, L. March, H. Lapsley, K. Tribe, A. Brnabic, B. Courtenay, P. Brooks (2000)
Determinants of willingness to pay for hip and knee joint replacement surgery for osteoarthritis.Rheumatology, 39 11
D. Gyrd-Hansen (2005)
Willingness to pay for a QALY: theoretical and methodological issues.PharmacoEconomics, 23 5
C. Sarawate, K. Brewer, Wenya Yang, P. Patel, H. Schumacher, K. Saag, A. Bakst (2006)
Gout medication treatment patterns and adherence to standards of care from a managed care perspective.Mayo Clinic proceedings, 81 7
Hyon Choi, E. Ford, Chaoyang Li, G. Curhan (2007)
Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey.Arthritis and rheumatism, 57 1
A. Riedel, M. Nelson, N. Joseph‐Ridge, K. Wallace, P. Macdonald, M. Becker (2004)
Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.The Journal of rheumatology, 31 8
Ware J.E.Jr., C. Sherburne (1992)
THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION, 30
J. Ware, C. Sherbourne (1992)
The MOS 36-Item Short-Form Health Survey (SF-36)
(1996)
Cost-effectiveness analysis as guide to resource allocation in health: roles and limitation
J. Ware (1994)
SF-36 physical and mental health summary scales : a user's manual
Introduction. Gout is a chronic painful inflammatory arthritis. The authors interviewed patients with chronic stable gout to assess their hypothetical willingness to pay (WTP) to be cured of their gout.Patients and Methods.Patients with gout were asked how much money they would be willing to pay every month out of pocket or as a co-pay to cure their gout. To assess determinants of WTP amounts, the authors performed stepwise multivariable linear regression analysis, controlling for demographics, health status, and relative concern about gout.Results.Of the 78 patients, 70 (90%) were male, 54 (69%) were Caucasian, 21 (27%) were African American, and 32 (41%) had annual incomes < $25,000. The median WTP amount was $25 ($0, $75) per month, and the mean (s) was $52 ($74) per month (range, $0-$350); 23 (30%) patients were unwilling to pay any amount. Patients who rated their gout as their top health concern were willing to pay a median of $63 ($25, $100) per month. In multivariable analysis, gout as the top health concern, greater frequency of gouty attacks over the past 1 y, and younger age were significantly associated with WTP amounts (R2 =0:19 ).Conclusion.Many patients with chronic gout would be willing to pay money every month in perpetuity to be cured of their gout. Younger patients, patients whose main health concern is gout, and patients with frequent attacks are willing to pay the most.
Medical Decision Making – SAGE
Published: Jul 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.